The History of Microdosing: From Ancient Ritual to Modern Science

Here’s the full revised article with all three Yoast issues addressed:

Before It Had a Name: The Long, Strange History of Microdosing

From Mesoamerican ritual to Silicon Valley boardrooms to double-blind placebo trials — the story of humanity’s quietest psychedelic experiment is older, stranger, and more scientifically interesting than you think.

By Joseph Santiago

Somewhere in Mesoamerica, thousands of years before the word “microdose” existed, someone made a choice. Instead of consuming the full ritual dose of psilocybin magic mushrooms — the dose that dissolves ego and opens the cosmos — they took less. A smaller amount. Enough to sharpen the mind, settle the emotions, carry them through the day. They didn’t write it down. They didn’t publish a study. But they understood something that the modern world is only now catching up to: that the power of a psychedelic substance isn’t only found at its peak.

Microdosing — the practice of taking sub-perceptual doses of psychedelics, typically around 1/10th of a full recreational dose — is one of the most talked-about wellness and cognitive enhancement practices of the 21st century. It has been covered by The New York Times, studied at Johns Hopkins, debated in parliamentary health committees, and quietly practiced by everyone from trauma therapists to FTSE 100 executives. But where did it actually come from? And what does the science, stripped of both hype and hysteria, actually tell us?

The answer requires traveling across centuries, continents, and scientific paradigms. It requires understanding that microdosing is simultaneously ancient and modern — a practice that has been perpetually rediscovered, suppressed, and rediscovered again. And it requires being honest about what we know, what we don’t, and what that means for you.

Part I: The Ancient Record

Before Science, There Was Ceremony

The cultural bedrock of psychedelic use goes back thousands of years. Indigenous cultures across Mesoamerica incorporated psilocybin mushrooms — called teonanácatl, roughly “flesh of the gods” — into ritual, healing, and cosmological practice. The Mazatec, Zapotec, and Mixtec peoples of Oaxaca treated these fungi as sacraments, not substances.

What often gets overlooked in the popular history is that not all indigenous use aimed at full, visionary doses. Healers and curanderas used variable amounts calibrated to the person, the purpose, and the context. Some traditions incorporated smaller, repeated doses for sustained clarity and emotional alignment rather than dramatic spiritual experience. James Fadiman, the psychologist who would later systematise modern microdosing, has acknowledged openly that his protocols represent a rediscovery rather than an invention — the knowledge was already there.

“The idea of using psychedelics as tools — not just for full trips — is ancient. We are not pioneers. We are students catching up.”
— Microdosing Institute, on the lineage of sub-perceptual use

This matters. When we talk about the “history” of microdosing, we are really talking about the history of its documentation — which is not the same thing at all. The undocumented practice almost certainly extends much further back.

Part II: The First Scientific Era (1950s–1970s)

Chemistry, Consciousness, and Albert Hofmann’s Quiet Experiment

On April 16, 1943 — a date psychedelic enthusiasts now celebrate annually as “Bicycle Day” — Swiss chemist Albert Hofmann accidentally absorbed a small amount of a compound he had synthesised five years earlier and largely forgotten. LSD-25. He then deliberately ingested a larger dose the following day and cycled home through Basel with the ground tilting beneath him and the edges of reality softening.

Hofmann went on to become arguably the world’s first deliberate microdoser. In his later years, long after authorities had prohibited LSD, he reported taking small amounts regularly — not to trip, but to access what he described as a subtle mental clarity, elevated mood, and something like refined perception. He called it a “medicine for the soul.” This wasn’t anecdote from a counterculture dropout. This was the molecule’s own discoverer, in his eighties, quietly experimenting with sub-perceptual doses and finding them valuable.

Meanwhile, throughout the 1950s and early 1960s, the broader scientific establishment conducted a remarkable range of low-dose psychedelic research. Studies explored LSD and psilocybin in contexts as varied as alcoholism treatment, depression, creativity enhancement, and palliative care for the dying. Early low-dose experiments appeared as far back as 1955. Researchers hadn’t yet coined the language of “microdosing” — but the fundamental curiosity was identical to what drives modern researchers.

Pioneer Profile: James Fadiman — The Architect of Modern Microdosing

A Harvard-educated psychologist who moved to Stanford, Fadiman participated in psychedelic research in the 1960s before prohibition shut everything down. His landmark work included helping design and run experiments where professionals — engineers, architects, mathematicians — took LSD doses and then worked on problems they had been stuck on for months. Most solved them.

Decades later, Fadiman picked this thread back up. His influence on the modern movement cannot be overstated — he gave it its structure, its language, and its ethical grounding.

The Great Shutdown

Then, abruptly: silence. Between 1966 and the early 1970s, governments criminalised LSD across most of the Western world. Authorities revoked research permits. Labs closed. Scientists who had spent years developing rigorous protocols received orders to stop. The knowledge didn’t disappear — instead, it migrated from academic journals into counterculture networks, from controlled settings into improvisatory ones.

The prohibition of psychedelics stands as one of the great scientific tragedies of the 20th century. Decades of promising research stopped mid-sentence. Careers derailed. And an entire generation of people who might have benefited from therapeutic psychedelic treatment received no treatment at all, or inadequate alternatives. We are still paying the cost of that political decision today.

Part III: The Underground Years (1970s–2000s)

Silence, But Not Absence

Microdosing didn’t stop during prohibition. It went quiet. Throughout the 1970s, ’80s, and ’90s, a scattered community of psychonauts continued to experiment privately, sharing findings through zines, mailing lists, and word of mouth. Low-dose LSD use circulated in certain music and arts communities — well-documented anecdotal evidence places it in the culture that grew up around the Grateful Dead. By the 1980s, certain preparations marketed at around 5 micrograms of LSD had emerged — a clear precursor to what we now call microdosing.

None of this was science. It was accumulated folk knowledge — imprecise, uncontrolled, undocumented. But it kept the idea alive during the decades when academic research could not. Consequently, when science eventually returned to psychedelics in the early 2000s, it wasn’t building from nothing. It was reconnecting with a living, breathing tradition that had never fully stopped.

Part IV: The Modern Movement (2011 — Present)

Fadiman Returns, and Everything Changes

The catalyst for modern microdosing’s emergence into mainstream consciousness was a single book published in 2011: James Fadiman’s The Psychedelic Explorer’s Guide. In it, Fadiman introduced the concept of sub-perceptual dosing with a structured protocol — what became known as the Fadiman Protocol: one day on, two days off, repeat.

The protocol’s elegance lies in its logic. The two rest days prevent tolerance from building and allow the nervous system to integrate changes without overstimulation. The doses — typically 0.1 to 0.3 grams of dried psilocybin mushroom, or 5 to 20 micrograms of LSD — are calibrated to produce effects below the threshold of ordinary perception. The goal is not to alter consciousness. It is to slightly tilt the playing field in your favour, day after day, in ways that compound over time.

Fadiman also did something methodologically important: he began collecting reports. Thousands of them. He built a crowdsourced dataset of self-reported microdosing experiences from people around the world, tracking what they took, when they took it, and what they noticed. It wasn’t a randomised controlled trial. But it was, for its time, the most comprehensive body of microdosing data that existed.

A Timeline of the Modern Era

2011 — Fadiman publishes The Psychedelic Explorer’s Guide, introducing the Fadiman Protocol and launching modern microdosing into public discourse.

2015 — Tech workers begin reporting microdosing for productivity and creativity. WIRED and Rolling Stone publish early mainstream coverage. The “biohacking” framing takes hold.

2017 — Ayelet Waldman publishes A Really Good Day, her memoir of a month microdosing LSD for mood stabilisation. It becomes a New York Times bestseller and brings the practice to a much wider audience, particularly women.

2019 — Mycologist Paul Stamets introduces his protocol combining psilocybin with Lion’s Mane mushroom and niacin, targeting neuroplasticity. The stack ignites global interest in stacked approaches to psychedelic wellness.

2021 — A landmark systematic review of 44 studies covering research from 1955 to 2021 maps what the evidence actually says about microdosing across mood, cognition, creativity, and clinical conditions.

2024 — New controlled research shows microdosing improving emotion regulation and reducing ADHD symptoms, with some effects persisting over time. The clinical picture begins to sharpen.

The Protocols Worth Knowing

Protocol 01 — The Fadiman Protocol: One day on, two days off. The original structured approach. Researchers designed it to prevent tolerance and allow integration. Most widely studied.

Protocol 02 — The Stamets Stack: Psilocybin + Lion’s Mane + Niacin. Four days on, three days off. Targets neuroplasticity and long-term cognitive resilience.

Protocol 03 — Intuitive / Everyday: Dose only when needed. Less structured, more responsive. Common among experienced users who have established their baseline.

Part V: What the Science Actually Says

Signals Through the Noise

Here is where intellectual honesty becomes non-negotiable. The research on microdosing is real, growing, and genuinely promising — but it is also early, limited, and complicated by methodological challenges. Anyone who tells you the science is settled is wrong. And anyone who tells you there’s nothing to see here is equally wrong. The truth is messier and more interesting than either position.

The most comprehensive review to date examined 44 studies spanning 1955 to 2021. Across that body of work, researchers found consistent signals that microdosing may positively influence mood and mental health outcomes, cognitive processing, creativity and divergent thinking, and perceptual experience including time perception and pain sensitivity. These are not trivial findings. Furthermore, they align with decades of anecdotal reports from people who have used these substances without clinical oversight. But researchers must hold them carefully, because many of the underlying studies are observational, self-reported, or conducted without placebo controls.

The Placebo Problem

The placebo issue represents the central scientific challenge. In some controlled trials, participants who believed they were microdosing — but weren’t — reported benefits that mirrored those of actual dosers. This doesn’t mean microdosing doesn’t work. Expectation and intention are themselves powerful variables in mental health. However, it does mean researchers cannot yet cleanly separate the pharmacological effects from the psychological ones — and that distinction matters enormously for designing effective clinical protocols.

“The placebo problem isn’t a reason to dismiss microdosing. It’s a reason to take the question more seriously.”

Where the Evidence Is Strongest

Certain conditions show particularly promising early signals. OCD research is older than most people realise — evidence for psilocybin’s effect on obsessive-compulsive patterns goes back to the 1960s, and a 2006 study showed significant symptom reduction. The mechanism makes neurobiological sense: psychedelics may interrupt the rigid, looping thought patterns that characterise OCD by temporarily disrupting the Default Mode Network and increasing neural plasticity.

ADHD represents a newer frontier. A 2024 study showed improvements in both emotion regulation and core ADHD symptom presentation, with some effects persisting beyond the active dosing period. This finding carries clinical significance — it suggests microdosing may do something structural to neural function, rather than simply providing temporary symptom relief.

Depression and anxiety represent the largest body of anecdotal evidence, though clinical research is still catching up. The most consistent user reports across every dataset — from Fadiman’s early collection to modern apps tracking thousands of users — describe reduced depressive symptoms, greater emotional flexibility, decreased anxiety, and improved quality of interpersonal relationships. “I’m nicer to people” appears in the data with striking regularity.

What We Likely Know vs. What We Don’t Yet Know

What we likely know: Microdosing changes subjective experience. Mood improvements appear frequently in reports. Cognitive processing may improve. OCD and ADHD show early clinical signals. Neuroplasticity mechanisms are plausible.

What we don’t yet know: The long-term safety profile. Optimal dosing for different people. Precise neurological mechanisms. Who it works for — and who it doesn’t. How to separate placebo from pharmacology.

Part VI: How It Actually Works (The Biology)

Four Mechanisms Worth Understanding

The neurobiological story of microdosing involves at least four intersecting systems, and understanding them helps make sense of why the effects look the way they do.

The primary mechanism is the serotonin system — specifically, the 5-HT2A receptor, the same receptor pathway that full psychedelic doses activate. Sub-perceptual doses interact with this receptor at levels that appear to modulate mood and cognition without triggering the full perceptual disruption of a trip. Think of it as tapping the system lightly rather than striking it hard.

Neuroplasticity is the second mechanism generating the most scientific excitement. Both psilocybin and LSD appear to promote dendritic growth and synaptic plasticity — essentially making the brain more flexible and more capable of forming new connections. This is why researchers are interested in microdosing for conditions that rigid neural patterns characterise: depression, OCD, addiction, and trauma. If you can soften the ruts in the road, behaviour change becomes more possible.

Third is the Default Mode Network — the brain’s background hum of self-referential thought, rumination, and narrative self-construction. Overactivity in the DMN associates with depression, anxiety, and ego-driven mental loops. Psychedelics, even at sub-perceptual doses, appear to quiet the DMN — consequently freeing cognitive resources for more present-focused, flexible thinking.

Fourth: emotional processing. Multiple studies and thousands of user reports suggest that microdosing increases what researchers describe as emotional flexibility — a greater capacity to feel, process, and move through emotional experiences without getting stuck. For many users, this is the most practically significant effect: not that they feel better exactly, but that they feel differently. More fluidly. With less rigidity.

Part VII: The Deeper Truth

This Is Not a Productivity Hack

Microdosing arrived in mainstream consciousness wearing Silicon Valley clothes. The early 2015–2018 wave of coverage focused overwhelmingly on tech workers seeking flow states, enhanced creativity, and competitive cognitive edge. This framing wasn’t wrong — those people exist, those experiences are real — but it was incomplete in ways that have distorted the public understanding of what microdosing actually is.

The deeper story — the one that connects the Mazatec healer to Albert Hofmann to James Fadiman to the thousands of people using structured protocols today — is not about productivity. It’s about subtle, sustained rewiring. Not “I feel better today” but “I behave differently over months.” Not performance optimisation, but something closer to what the contemplative traditions call cultivation — the gradual, patient reshaping of perception, habit, and relationship through repeated, intentional practice.

This is why the people who report the most significant long-term benefits from microdosing are rarely those who approach it as a biohack. They are the ones who approach it the way indigenous traditions always approached their most powerful medicines: with reverence, with structure, with awareness, and with patience for a process that unfolds over time.

The Scholars Worth Studying

Five Researchers Who Shaped What We Know

James Fadiman — The protocolist. He gave modern microdosing its structure and ethical grounding.

Paul Stamets — The mycologist. He expanded the conversation to stacked approaches and neuroplasticity.

Robin Carhart-Harris — The neuroscientist. His fMRI research on psychedelics and the Default Mode Network is foundational for understanding the mechanism.

David Nutt — The pharmacologist and policy critic. He has pushed for evidence-based drug policy reform for decades.

Roland Griffiths — The clinician. His psilocybin trials at Johns Hopkins for depression, addiction, and end-of-life distress set the gold standard for modern psychedelic research.

Where We Go From Here

The arc of microdosing’s history is not a straight line. It is a spiral — the same insights returning in different forms, in different eras, each time a little more articulate, a little more rigorous, a little better supported by the tools available to the people living in that moment. Indigenous healers knew it first, in the body. Chemists like Hofmann knew it secondhand, in the lab. Psychologists like Fadiman put structure around it. Today, neuroscientists are explaining the machinery beneath it.

We are, at this moment, living through the most scientifically serious period in microdosing’s history. The research is accelerating. The political climate is shifting — cautiously, imperfectly, but shifting. Moreover, the number of people engaging with these substances thoughtfully — with protocols, intention, and honest self-observation — is larger than at any previous point in documented history.

What the history asks of us is honesty. Not the honesty of enthusiasm — that comes easily. The harder honesty: acknowledging what we don’t know, holding the evidence carefully, resisting the urge to over-claim or under-claim. The people who will do the most good for this field — whether as researchers, practitioners, advocates, or community builders — are those who can hold both the ancient and the scientific, the personal and the rigorous, the promising and the uncertain, all at once. Without resolving them too quickly. Without needing the story to be simpler than it is.

The practice is ancient. The science is young. The conversation is just getting started.